Objective To explore the effects of Shenyuan Yiqi Huoxue Capsules on cardiopulmonary exercise function and quality of life in patients with ischemic cardiomyopathy.Methods Totally 66 patients with ischemic cardiomyopathy were divided into treatment group and control group using random number table method,with 33 cases in each group.Both groups received standardized Western medicine treatment,and the treatment group was additionally given Shenyuan Yiqi Huoxue Capsules,the control group was given Shenyuan Yiqi Huoxue Capsules simulator,three capsules per time,three times a day,orally.The observation period was 30 days.To evaluate the efficacy of TCM syndrome in two groups.The observation indicators included baseline data,TCM syndrome scores,cardiopulmonary exercise test detection indicators,MLHFQ score,SF-36 score,echocardiographic indicators,N-terminal pro-B-type natriuretic peptide(NT-pro BNP)and safety indicators.Results The total effective rate of the treatment group was 93.94%(31/33),while that of the control group was 78.79%(26/33).The treatment group was significantly better than the control group(P<0.05).Compared with before treatment,the TCM syndrome scores of the two groups of patients decreased(P<0.05),and after treatment,the TCM syndrome score of the treatment group was lower than that of the control group(P<0.05).Compared with before treatment,the peak oxygen uptake(peak VO2),anaerobic threshold(AT)and peak oxygen pulse(peak O2 pulse)of both groups of patients increased,while the carbon dioxide ventilation equivalent slope(VE/VCO2 slope)decreased(P<0.05).After treatment,the treatment group had higher peak VO2,AT and peak O2 pulse than the control group,while the VE/VCO2 slope was lower than the control group(P<0.05).Compared with before treatment,both groups of patients showed a decrease in MLHFQ score and an increase in SF-36 score(P<0.05);after treatment,the MLHFQ score in the treatment group was lower than that in the control group,and the SF-36 score was higher than that in the control group(P<0.05).Compared with before treatment,both groups of patients showed a decrease in left ventricular end systolic diameter,left ventricular end diastolic diameter and NT-pro BNP levels,while myocardial motion index and left ventricular ejection fraction increased(P<0.05);after treatment,the treatment group showed a decrease in left ventricular end systolic diameter,left ventricular end diastolic diameter and NT-pro BNP levels,while myocardial motion index and left ventricular ejection fraction increased(P<0.05).During the treatment period,no adverse reactions such as dizziness,nausea,vomiting or diarrhea were found in both groups of patients.Conclusion Shenyuan Yiqi Huoxue Capsules can significantly improve the clinical efficacy of ischemic cardiomyopathy patients,alleviate TCM symptoms,improve their cardiorespiratory function and quality of life.

Objective To observe the clinical efficacy of Shenyuan Yiqi Huoxue Capsules for the treatment of stable angina pectoris combined with ventricular premature beat.Methods Totally 70 patients with stable angina pectoris combined with ventricular premature beat were selected,and were divided into control group and experimental group using random number table method,with 35 cases in each group.The control group was given metoprolol tartrate tablets,25 mg/time,twice a day,orally on the basis of conventional Western medicine treatment;the experimental group was treated with Shenyuan Yiqi Huoxue Capsules on the basis of control group treatment,400 mg each time,three times a day.The course of treatment for both groups was three months.The frequency and efficacy of 24 hour ventricular premature beats,TCM syndrome scores and efficacy,heart rate variability(HRV),Seattle Angina Questionnaire(SAQ)score were observed in the two groups before and after treatment.Adverse reactions of both group were monitored.Results The experimental group shed 2 cases,and the control group shed 1 case.The total effective rate of premature ventricular contractions in the experimental group was 96.97%(32/33),while in the control group it was 82.44%(28/34).The experimental group was higher than the control group(P<0.05);the total effective rate of TCM syndrome in the experimental group was 93.94%(31/33),while in the control group it was 73.53%(25/34).The experimental group was higher than the control group(P<0.05).Compared with before treatment,the number of 24 hour ventricular premature beats in both groups decreased significantly after treatment(P<0.01).After treatment,the experimental group had significantly lower 24 hour ventricular premature beats compared to the control group(P<0.05).Compared with before treatment,both groups showed significant increases in HRV indicators and SAQ scores after treatment(P<0.01);after treatment,the HRV indicators and SAQ scores in the experimental group were significantly higher than those in the control group(P<0.05).Compared with before treatment,the TCM syndrome scores of palpitations,chest tightness,shortness of breath,fatigue,spontaneous sweating and insomnia in both groups were significantly reduced after treatment(P<0.01).After treatment,the experimental group had significantly lower TCM symptoms scores such as palpitations,chest tightness,shortness of breath,fatigue,spontaneous sweating and insomnia(P<0.05).There were no adverse reactions in either group.Conclusion Shenyuan Yiqi Huoxue Capsules have a clear effect on the treatment of stable angina pectoris combined with ventricular premature beat,which can reduce the frequency of 24 hour ventricular premature beats,relieve TCM symptoms,improve HRV,and increase the score of SAQ without clinical adverse reactions.

Neurofibromatosis type 1 (NF1) presents with a diverse range of symptoms that can affect the skin, bones, eyes, central nervous system, and other organs. This article reports the diagnosis and treatment process of a patient with NF1 complicated by bilateral severe-to-profound sensorineural hearing loss. Genetic testing revealed a heterozygous variant of NF1 NM_ 000267.3: c.4054_ 4058del(p.Ser1352LeufsTer20, supporting the diagnosis of NF1. After thorough evaluation, a right cochlear implantation was performed, yielding satisfactory postoperative results. This case suggests that NF1 patients may exhibit phenotypic heterogeneity and atypicality, providing a reference for clinicians in the diagnosis and treatment of such patients.

BACKGROUND: The available evidence regarding the benefits of percutaneous coronary intervention (PCI) on patients receiving dialysis with coronary artery disease (CAD) is limited and inconsistent. This study aimed to evaluate the association between PCI and clinical outcomes as compared with medical therapy alone in patients undergoing dialysis with CAD in China. METHODS: This multicenter, retrospective study was conducted in 30 tertiary medical centers across 12 provinces in China from January 2015 to June 2021 to include patients on dialysis with CAD. The primary outcome was major adverse cardiovascular events (MACE), defined as a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Secondary outcomes included all-cause death, the individual components of MACE, and Bleeding Academic Research Consortium criteria types 2, 3, or 5 bleeding. Multivariable Cox proportional hazard models were used to assess the association between PCI and outcomes. Inverse probability of treatment weighting (IPTW) and propensity score matching (PSM) were performed to account for potential between-group differences. RESULTS: Of the 1146 patients on dialysis with significant CAD, 821 (71.6%) underwent PCI. After a median follow-up of 23.0 months, PCI was associated with a 43.0% significantly lower risk for MACE (33.9% [ n  = 278] vs . 43.7% [ n  = 142]; adjusted hazards ratio 0.57, 95% confidence interval 0.45-0.71), along with a slightly increased risk for bleeding outcomes that did not reach statistical significance (11.1% vs . 8.3%; adjusted hazards ratio 1.31, 95% confidence interval, 0.82-2.11). Furthermore, PCI was associated with a significant reduction in all-cause and cardiovascular mortalities. Subgroup analysis did not modify the association of PCI with patient outcomes. These primary findings were consistent across IPTW, PSM, and competing risk analyses. CONCLUSION This study indicated that PCI in patients on dialysis with CAD was significantly associated with lower MACE and mortality when comparing with those with medical therapy alone, albeit with a slightly increased risk for bleeding events that did not reach statistical significance.
Humans ; Percutaneous Coronary Intervention/methods* ; Male ; Female ; Coronary Artery Disease/drug therapy* ; Retrospective Studies ; Renal Dialysis/methods* ; Middle Aged ; Aged ; China ; Proportional Hazards Models ; Treatment Outcome

Objective To observe the clinical efficacy of Yiqi Shengjin Powder combined with conventional Western medicine in the treatment of diabetic heart disease,and the effects on cardiac autonomic nervous function,cardiac function and inflammatory factors.Methods Totolly 84 patients with diabetic heart disease were divided into control group and treatment group with random number table method,with 42 cases in each group.The control group developed personalized hypoglycemic plans and heart disease treatment drugs based on the patients'blood glucose levels.The treatment group took Yiqi Shengjin Powder in addition to the control group,and after an interval of 0.5 hours with Western medicine,they took it with warm water,2 bags each time,twice a day,for 6 consecutive weeks of treatment.TCM therapeutic effects of two groups,TCM symptoms score,sinus rhythm RR interval(SDNN),root mean square of adjacent interval difference(RMSSD),standard deviation of RR interval mean(SDANN),high frequency(HF),low frequency(LF),various indicators of cardiac function[left ventricular ejection fraction(LVEF),left ventricular end systolic diameter(LVESD),left ventricular end diastolic diameter(LVEDD)],inflammatory factors[interleukin-6(IL-6),transforming growth factor beta 1(TGF-β1),tumor necrosis factor alpha(TNF-α)]and adverse reactions before and after treatment were observed.Results The total effective rate of the treatment group was 90.48%(38/42),while that of the control group was 73.81%(31/42).The therapeutic effect of the treatment group was better than that of the control group(P<0.05).Compared with before treatment,both group showed a significant decrease in chest pain,tightness,palpitations,palpitations and shortness of breath,excessive dreaming and sweating,five heart restlessness and fatigue scores after treatment(P<0.05);after treatment,the treatment group showed a decrease in chest pain,tightness,palpitations,palpitations and shortness of breath,excessive dreaming and sweating,five heart restlessness and fatigue scores compared to the control group(P<0.05).Compared with before treatment,both group showed a significant increase in SDNN,SDANN,RMSSD,HF and LF after treatment(P<0.05);after treatment,the SDNN,SDANN,RMSSD,HF and LF levels in the treatment group were significantly higher than those in the control group(P<0.001).Compared with before treatment,LVEF increased,LVEDD and LVESD decreased in both group after treatment(P<0.001);after treatment,the LVEF of the treatment group increased compared to the control group,while LVEDD and LVESD decreased compared to the control group(P<0.001).Compared with before treatment,the serum levels of TNF-α,TGF-β1 and IL-6 in both groups decreased(P<0.001);after treatment,the serum levels of TNF-α,TGF-β1 and IL-6 in the treatment group were lower than those in the control group(P<0.001).There was no statistical significance in adverse reactions between the two groups(P>0.05).Conclusion Yiqi Shengjin Powder combined with conventional Western medicine therapy for patients with diabetes heart disease has significant effect and high safety.It can effectively improve patients'cardiac autonomic nervous function and cardiac function,reduce inflammatory reaction,and has no serious adverse reactions.

Objective To explore the effects of Shenyuan Yiqi Huoxue Capsules on cardiopulmonary exercise function and quality of life in patients with ischemic cardiomyopathy.Methods Totally 66 patients with ischemic cardiomyopathy were divided into treatment group and control group using random number table method,with 33 cases in each group.Both groups received standardized Western medicine treatment,and the treatment group was additionally given Shenyuan Yiqi Huoxue Capsules,the control group was given Shenyuan Yiqi Huoxue Capsules simulator,three capsules per time,three times a day,orally.The observation period was 30 days.To evaluate the efficacy of TCM syndrome in two groups.The observation indicators included baseline data,TCM syndrome scores,cardiopulmonary exercise test detection indicators,MLHFQ score,SF-36 score,echocardiographic indicators,N-terminal pro-B-type natriuretic peptide(NT-pro BNP)and safety indicators.Results The total effective rate of the treatment group was 93.94%(31/33),while that of the control group was 78.79%(26/33).The treatment group was significantly better than the control group(P<0.05).Compared with before treatment,the TCM syndrome scores of the two groups of patients decreased(P<0.05),and after treatment,the TCM syndrome score of the treatment group was lower than that of the control group(P<0.05).Compared with before treatment,the peak oxygen uptake(peak VO2),anaerobic threshold(AT)and peak oxygen pulse(peak O2 pulse)of both groups of patients increased,while the carbon dioxide ventilation equivalent slope(VE/VCO2 slope)decreased(P<0.05).After treatment,the treatment group had higher peak VO2,AT and peak O2 pulse than the control group,while the VE/VCO2 slope was lower than the control group(P<0.05).Compared with before treatment,both groups of patients showed a decrease in MLHFQ score and an increase in SF-36 score(P<0.05);after treatment,the MLHFQ score in the treatment group was lower than that in the control group,and the SF-36 score was higher than that in the control group(P<0.05).Compared with before treatment,both groups of patients showed a decrease in left ventricular end systolic diameter,left ventricular end diastolic diameter and NT-pro BNP levels,while myocardial motion index and left ventricular ejection fraction increased(P<0.05);after treatment,the treatment group showed a decrease in left ventricular end systolic diameter,left ventricular end diastolic diameter and NT-pro BNP levels,while myocardial motion index and left ventricular ejection fraction increased(P<0.05).During the treatment period,no adverse reactions such as dizziness,nausea,vomiting or diarrhea were found in both groups of patients.Conclusion Shenyuan Yiqi Huoxue Capsules can significantly improve the clinical efficacy of ischemic cardiomyopathy patients,alleviate TCM symptoms,improve their cardiorespiratory function and quality of life.

Objective To observe the clinical efficacy of Shenyuan Yiqi Huoxue Capsules for the treatment of stable angina pectoris combined with ventricular premature beat.Methods Totally 70 patients with stable angina pectoris combined with ventricular premature beat were selected,and were divided into control group and experimental group using random number table method,with 35 cases in each group.The control group was given metoprolol tartrate tablets,25 mg/time,twice a day,orally on the basis of conventional Western medicine treatment;the experimental group was treated with Shenyuan Yiqi Huoxue Capsules on the basis of control group treatment,400 mg each time,three times a day.The course of treatment for both groups was three months.The frequency and efficacy of 24 hour ventricular premature beats,TCM syndrome scores and efficacy,heart rate variability(HRV),Seattle Angina Questionnaire(SAQ)score were observed in the two groups before and after treatment.Adverse reactions of both group were monitored.Results The experimental group shed 2 cases,and the control group shed 1 case.The total effective rate of premature ventricular contractions in the experimental group was 96.97%(32/33),while in the control group it was 82.44%(28/34).The experimental group was higher than the control group(P<0.05);the total effective rate of TCM syndrome in the experimental group was 93.94%(31/33),while in the control group it was 73.53%(25/34).The experimental group was higher than the control group(P<0.05).Compared with before treatment,the number of 24 hour ventricular premature beats in both groups decreased significantly after treatment(P<0.01).After treatment,the experimental group had significantly lower 24 hour ventricular premature beats compared to the control group(P<0.05).Compared with before treatment,both groups showed significant increases in HRV indicators and SAQ scores after treatment(P<0.01);after treatment,the HRV indicators and SAQ scores in the experimental group were significantly higher than those in the control group(P<0.05).Compared with before treatment,the TCM syndrome scores of palpitations,chest tightness,shortness of breath,fatigue,spontaneous sweating and insomnia in both groups were significantly reduced after treatment(P<0.01).After treatment,the experimental group had significantly lower TCM symptoms scores such as palpitations,chest tightness,shortness of breath,fatigue,spontaneous sweating and insomnia(P<0.05).There were no adverse reactions in either group.Conclusion Shenyuan Yiqi Huoxue Capsules have a clear effect on the treatment of stable angina pectoris combined with ventricular premature beat,which can reduce the frequency of 24 hour ventricular premature beats,relieve TCM symptoms,improve HRV,and increase the score of SAQ without clinical adverse reactions.

Objective To observe the clinical efficacy of Yiqi Shengjin Powder combined with conventional Western medicine in the treatment of diabetic heart disease,and the effects on cardiac autonomic nervous function,cardiac function and inflammatory factors.Methods Totolly 84 patients with diabetic heart disease were divided into control group and treatment group with random number table method,with 42 cases in each group.The control group developed personalized hypoglycemic plans and heart disease treatment drugs based on the patients'blood glucose levels.The treatment group took Yiqi Shengjin Powder in addition to the control group,and after an interval of 0.5 hours with Western medicine,they took it with warm water,2 bags each time,twice a day,for 6 consecutive weeks of treatment.TCM therapeutic effects of two groups,TCM symptoms score,sinus rhythm RR interval(SDNN),root mean square of adjacent interval difference(RMSSD),standard deviation of RR interval mean(SDANN),high frequency(HF),low frequency(LF),various indicators of cardiac function[left ventricular ejection fraction(LVEF),left ventricular end systolic diameter(LVESD),left ventricular end diastolic diameter(LVEDD)],inflammatory factors[interleukin-6(IL-6),transforming growth factor beta 1(TGF-β1),tumor necrosis factor alpha(TNF-α)]and adverse reactions before and after treatment were observed.Results The total effective rate of the treatment group was 90.48%(38/42),while that of the control group was 73.81%(31/42).The therapeutic effect of the treatment group was better than that of the control group(P<0.05).Compared with before treatment,both group showed a significant decrease in chest pain,tightness,palpitations,palpitations and shortness of breath,excessive dreaming and sweating,five heart restlessness and fatigue scores after treatment(P<0.05);after treatment,the treatment group showed a decrease in chest pain,tightness,palpitations,palpitations and shortness of breath,excessive dreaming and sweating,five heart restlessness and fatigue scores compared to the control group(P<0.05).Compared with before treatment,both group showed a significant increase in SDNN,SDANN,RMSSD,HF and LF after treatment(P<0.05);after treatment,the SDNN,SDANN,RMSSD,HF and LF levels in the treatment group were significantly higher than those in the control group(P<0.001).Compared with before treatment,LVEF increased,LVEDD and LVESD decreased in both group after treatment(P<0.001);after treatment,the LVEF of the treatment group increased compared to the control group,while LVEDD and LVESD decreased compared to the control group(P<0.001).Compared with before treatment,the serum levels of TNF-α,TGF-β1 and IL-6 in both groups decreased(P<0.001);after treatment,the serum levels of TNF-α,TGF-β1 and IL-6 in the treatment group were lower than those in the control group(P<0.001).There was no statistical significance in adverse reactions between the two groups(P>0.05).Conclusion Yiqi Shengjin Powder combined with conventional Western medicine therapy for patients with diabetes heart disease has significant effect and high safety.It can effectively improve patients'cardiac autonomic nervous function and cardiac function,reduce inflammatory reaction,and has no serious adverse reactions.

Objective To explore the effects of the regulation of JAK/STAT signaling pathway by the therapy of astringent ulcer and muscle inducing enema on colon injury and mucosal barrier in ulcerative colitis(UC)model rats.Methods A rat model of ulcerative colitis was established using 2,4,6-trinitrobenzenesulfonic acid/ethanol method.The model was randomly divided into a normal control group(without modeling),a model group,a positive drug group(mesalazine sustained-release granules 0.42 g·kg-1),a high dose of Lianchuang Shengji Formula(enema 10.5 g·kg-1),a medium dose(enema 5.25 g·kg-1),and a low dose group(enema 2.62 g·kg-1).Compare the fecal occult blood,degree of colonic mucosal damage,and pathological changes of rats in each group,and detect the expression of JAK2,STAT3 proteins,and their phosphorylated proteins in colon tissue using Western blot method.Results The results showed that the mesalazine group,the medium and high-dose groups of Lianchuang Shengji Formula could increase the body mass of rats,reduce fecal occult blood score,improve colon damage,and achieve pathological results;The mesalazine group and the low,medium,and high dose groups of Lianchuang Shengji can downregulate the expression of p-JAK2 and p-STAT3 proteins(compared with the model group,P＜0.05),with the high-dose group being the most significant(P＜0.01).The apoptosis rate of colon tissue significantly decreased(P＜0.05).Conclusion The enema therapy of astringent ulcer and promoting muscle growth can significantly improve the pathological scores of bloody stools and colon injury in rats with ulcerative colitis.The mechanism may be related to the inhibition of JAK2 and STAT3 phosphorylation protein expression,and further inhibition of the JAK/STAT signaling pathway.

Objective To explore the effects of the regulation of JAK/STAT signaling pathway by the therapy of astringent ulcer and muscle inducing enema on colon injury and mucosal barrier in ulcerative colitis(UC)model rats.Methods A rat model of ulcerative colitis was established using 2,4,6-trinitrobenzenesulfonic acid/ethanol method.The model was randomly divided into a normal control group(without modeling),a model group,a positive drug group(mesalazine sustained-release granules 0.42 g·kg-1),a high dose of Lianchuang Shengji Formula(enema 10.5 g·kg-1),a medium dose(enema 5.25 g·kg-1),and a low dose group(enema 2.62 g·kg-1).Compare the fecal occult blood,degree of colonic mucosal damage,and pathological changes of rats in each group,and detect the expression of JAK2,STAT3 proteins,and their phosphorylated proteins in colon tissue using Western blot method.Results The results showed that the mesalazine group,the medium and high-dose groups of Lianchuang Shengji Formula could increase the body mass of rats,reduce fecal occult blood score,improve colon damage,and achieve pathological results;The mesalazine group and the low,medium,and high dose groups of Lianchuang Shengji can downregulate the expression of p-JAK2 and p-STAT3 proteins(compared with the model group,P＜0.05),with the high-dose group being the most significant(P＜0.01).The apoptosis rate of colon tissue significantly decreased(P＜0.05).Conclusion The enema therapy of astringent ulcer and promoting muscle growth can significantly improve the pathological scores of bloody stools and colon injury in rats with ulcerative colitis.The mechanism may be related to the inhibition of JAK2 and STAT3 phosphorylation protein expression,and further inhibition of the JAK/STAT signaling pathway.